RC18 160 mg

BIOLOGICAL2 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Neuromyelitis Optica Spectrum DisordersPrimary Sjögren's Syndrome

Phase 2

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

CompletedNCT04078386

RemeGen Co., Ltd.Primary Sjögren's Syndrome

Start: 2019-11-21End: 2021-10-26Updated: 2026-05-27

Phase 3

A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

TerminatedNCT03330418

RemeGen Co., Ltd.Neuromyelitis Optica Spectrum Disorders

Start: 2018-01-29End: 2026-04-03Updated: 2026-04-13

Related Papers

Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial

Lara D. Veeken2023-06-3056 citations

Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study

CNS Neuroscience & Therapeutics2022-07-1831 citations